The Federal Ministry of Education and Research funds ImevaX with $7.5m.

Munich Institute of Technology’s (Tum) biotech spin-out biotech ImevaX has received further support from the Federal Ministry of Education and Research. The ministry is now funding the company with a Go Bio Phase II grant worth €5.9m ($7.5m).

The biotech is based on research by Markus Gerhard and Dirk Bursch at the university’s Institute of Medical Microbiology, Immunology and Hygiene. It is commercialising vaccines for chronic and nosocomial infectious diseases.

Lead drug candidate IMX is a vaccine against a bacterial…